FDA approves muscular dystrophy drug rejected by the agency in the past

National News

This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys 53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months earlier. (Sarepta Therapeutics via AP)

WASHINGTON (AP) — U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago.

The ruling marks the second time the Food and Drug Administration has granted preliminary approval for the drug based on early results and is likely to stoke questions about its standards for clearing largely unproven medications.

The FDA said late Thursday it approved Sarepta Therapeutics’ Vyondys 53 for patients with a form of Duchenne’s muscular dystrophy. Duchenne’s affects about 1 in every 3,600 boys in the U.S., causing muscle weakness, loss of movement and early death, usually when patients are in their 20s or 30s. The drug is for a specific type that affects about 8 percent of boys with Duchenne’s.

In August, the FDA appeared to reject the injectable medication, sending a letter to the company flagging risks of infections and kidney injury. But Sarepta disputed the decision, raising it to FDA’s drug center leadership. The company resubmitted its application and data, and the FDA reversed its decision, according to a Sarepta press release.

The surprise announcement sent company shares rocketing more than 36% in trading Friday. But some Wall Street analysts said the approval suggests loosening standards at the agency.

“The abruptness of the decision making at the agency does not inspire confidence, in our view,” analyst Debjit Chattopadhyay wrote in a note to investors.

It’s the second time a Sarepta drug has followed an unusual path to approval. In 2016, FDA leaders cleared the company’s first muscular dystrophy drug, overruling agency reviewers who said there was little evidence it worked. The decision also followed an intense lobbying campaign by patients’ families, politicians and physicians. Agency critics suggested the FDA may have bowed to outside pressure.

Vyondys received “accelerated approval” based on preliminary results showing it boosts a protein that aids the growth of muscle fibers. But the drug has not yet been shown to improve patients’ mobility or health. The FDA is requiring Sarepta to conduct follow-up studies on those measures for both drugs. If the company fails to show the drugs help patients, the FDA can withdraw approval — though it rarely does so.

The follow-up study for Vyondys is due by 2024. The drug will cost $300,000 per year for the typical patient — a child weighing 44 pounds, the company said. That’s the same price as Sarepta’s earlier drug.

Analysts said the unexpected decision could bode well for other experimental drugs with questionable study results, including a closely watched drug Alzheimer’s drug that will soon come before the agency.

The drug’s developers reported results in October suggesting their medication could be the first to slow mental decline in Alzheimer’s. But many experts are skeptical, noting unusual study changes and analyses used during the drug’s development.

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Recent Videos

Tuesday, February 25th, 2020 - KX Storm Team Evening Forecast - Dave Holder

Thumbnail for the video titled "Tuesday, February 25th, 2020 - KX Storm Team Evening Forecast - Dave Holder"

Minot Mischief

Thumbnail for the video titled "Minot Mischief"

Special Olympics

Thumbnail for the video titled "Special Olympics"

Hope for Haiti

Thumbnail for the video titled "Hope for Haiti"

KX Storm Team Full Evening Forecast w/Tom Schrader 2/25

Thumbnail for the video titled "KX Storm Team Full Evening Forecast w/Tom Schrader 2/25"

Coronavirus Impacts

Thumbnail for the video titled "Coronavirus Impacts"

YHF

Thumbnail for the video titled "YHF"

Teacher Shortage

Thumbnail for the video titled "Teacher Shortage"

Law Enforcement

Thumbnail for the video titled "Law Enforcement"

KX Storm Team #OneMinuteForecast w/Tom Schrader 2/25

Thumbnail for the video titled "KX Storm Team #OneMinuteForecast w/Tom Schrader 2/25"

Amber's Tuesday Morning #OneMinuteForecast 2/25

Thumbnail for the video titled "Amber's Tuesday Morning #OneMinuteForecast 2/25"

Tuesday Forecast: Partly sunny with cooler afternoon highs

Thumbnail for the video titled "Tuesday Forecast: Partly sunny with cooler afternoon highs"

Doug Update

Thumbnail for the video titled "Doug Update"

Zero Waste Week

Thumbnail for the video titled "Zero Waste Week"

Region 7 Girls Basketball

Thumbnail for the video titled "Region 7 Girls Basketball"

Region 5 Girls Basketball

Thumbnail for the video titled "Region 5 Girls Basketball"

Minot City Council Meeting

Thumbnail for the video titled "Minot City Council Meeting"

Fires Attorney

Thumbnail for the video titled "Fires Attorney"

One Basin Program

Thumbnail for the video titled "One Basin Program"

Safety Council

Thumbnail for the video titled "Safety Council"
More Video

KX News Trending Stories

Don't Miss

Daily Pledge

More Daily Pledge